Retrophin Announces Proposed Public Offering of Common Stock
June 08, 2020 16:01 ET
|
Retrophin, Inc.
SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering, subject...
Retrophin Reports First Quarter 2020 Financial Results
May 11, 2020 16:01 ET
|
Retrophin, Inc.
Enrollment continues in the pivotal DUPLEX and PROTECT studies of sparsentan DUPLEX Study of sparsentan in FSGS enrolled first 190 patients required for interim proteinuria analysis Net product...
Retrophin to Report First Quarter 2020 Financial Results
April 27, 2020 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, April 27, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report first quarter 2020 financial results on Monday, May 11, 2020 after the close of the U.S....
Retrophin to Present at Upcoming Investor Conferences
February 19, 2020 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming investor conferences in February and March:...
Retrophin to Report Fourth Quarter and Full Year 2019 Financial Results
February 10, 2020 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report fourth quarter and full year 2019 financial results on Monday, February 24, 2020 after the...
Retrophin Provides Corporate Update and 2020 Outlook
January 13, 2020 06:59 ET
|
Retrophin, Inc.
SAN DIEGO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the...
Retrophin Reports Third Quarter 2019 Financial Results
October 30, 2019 16:01 ET
|
Retrophin, Inc.
Enrollment on-track in pivotal Phase 3 clinical trials to support registration of sparsentan for patients with FSGS and IgAN Third quarter revenues rose nine percent to $44 million ...
Retrophin Announces Appointment of Peter Heerma as Chief Commercial Officer
October 01, 2019 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Peter Heerma as chief commercial officer, effective immediately. In this newly created...
Retrophin to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 02, 2019 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage, chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare...
Retrophin Doses First Patient in Pivotal Phase 3 PROTECT Study of Sparsentan for the Treatment of IgA Nephropathy
December 27, 2018 08:00 ET
|
Retrophin, Inc.
SAN DIEGO, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first patient has been dosed in the PROTECT Study, a global, pivotal Phase 3 clinical trial...